In 2011, Sight Sciences was founded to change the way the practice of ophthalmology and optometry thinks about and treats the leading causes of eye disease. The company’s efforts have focused on pioneering technology-driven solutions that address the underlying physiology of ophthalmic disease.
Supported by leading medical technology and private equity investors, Sight Sciences operates two business lines: surgical and non-surgical systems. Its surgical product portfolio consists of the TRAB™360 and VISCO™360 surgical systems for use by ophthalmologists. Its non-surgical product portfolio consists of its U.S. distributed TearCare™ technologies for use by ophthalmologists and optometrists.